Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00900133 · ClinicalTrials.gov registry record
Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer
A clinical trial, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- 60
- Enrollment target
NCT00900133: Completed study, sponsored by Case Comprehensive Cancer Center.
NCT00900133 is a clinical trial that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00900133 has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
RATIONALE: Measuring levels of calgranulin A and calgranulin B in the blood of patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to breast cancer. PURPOSE: This laboratory study is measuring calgranulin A and calgranulin B levels in the blood of patients with newly diagnosed stage I, stage II, or stage III breast cancer.
Interventions
- OTHER laboratory biomarker analysis
- OTHER immunoenzyme technique
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-12 |
What the finished NCT00900133 record still lists
NCT00900133 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00900133 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00900133 about?
NCT00900133 is a clinical study titled "Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer". RATIONALE: Measuring levels of calgranulin A and calgranulin B in the blood of patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to breast cancer. PURPOSE: This laboratory study is measuring calgranulin A and calgranulin B levels in the ...
What is the current status of trial NCT00900133?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2005-01. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00900133?
The interventions under investigation include: laboratory biomarker analysis (OTHER), immunoenzyme technique (OTHER).
Who is sponsoring clinical trial NCT00900133?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia